In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Rising Leaders Innovation Medical Device

From Nokia To Thyroid Monitoring – Via The Digital Hearing Aid Industry

Risk Averse Business Developer Sees Skills Converge In Targeted Home Monitoring Solution

  • Interviews

Executive Summary

Medtech was not on Jesper Kimer’s radar when pioneering mobile phone company Nokia took him into its graduate program. A few career turns later, having fulfilled a desire to become an entrepreneur, his expertise and interests met in the middle when he co-founded thyroid disorder home monitoring start-up, HEI Therapeutics.

Table

View full table

Topics

Tags:
Rising Leaders Innovation Medical Device
Latest Headlines

How To Grow A Biotech - Insights From Scientist-Entrepreneurs

Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline

US FTC Targets Pharma Patent Abuse: What You Need to Know

For BMS, Launching New Products Is The Start Of The Battle

See All
UsernamePublicRestriction

Register

IV148504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By